Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 12, 2013, Pages 2354-2363

  Kasperzyk, Julie L ^a   Finn, Stephen P ^c,d   Flavin, Richard ^c,d   Fiorentino, Michelangelo ^a,c,e   Lis, Rosina ^c   Hendrickson, Whitney K ^a   Clinton, Steven K ^f   Sesso, Howard D ^a   Giovannucci, Edward L ^a   Stampfer, Meir J ^a   Loda, Massimo ^b,c   Mucci, Lorelei A ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d ST JAMES S HOSPITAL   (Ireland)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; VITAMIN D RECEPTOR;

AGED; APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; DOUBLE BLIND PROCEDURE; ELECTRORETINOGRAM; FOLLOW UP; GENE EXPRESSION; GLEASON SCORE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

AGED; CELL GROWTH PROCESSES; COHORT STUDIES; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 84890077560     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0668     Document Type: Article

References (41)

1. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54: 1807-11.
2. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissuespecificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006; 236:229-38.
3. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:637-40.
4. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998;82: 2256-61.
5. Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, et al. Prostatespecific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007;38:696-701.
6. Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003;9:6357-62.
7. Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 2011;71:281-8.
8. Gregorakis AK, Holmes EH, Murphy GP. Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol 1998;16:2-12.
9. Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2007;2:182-90.
10. Okegawa T, Nutahara K, Higashihara E. Preoperative nested reverse transcription-polymerase chain reaction for prostate specific membrane antigen predicts biochemical recurrence after radical prostatectomy. BJU Int 1999;84:112-7.
11. Mitsiades CS, Lembessis P, Sourla A, Milathianakis C, Tsintavis A, Koutsilieris M. Molecular staging by RT-pCR analysis for PSA and PSMAin peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin Exp Metastasis 2004;21: 495-505.
12. Joung JY, Cho KS, Chung HS, Cho IC, Kim JE, Seo HK, et al. Prostate specific membrane antigen mRNA in blood as a potential predictor of biochemical recurrence after radical prostatectomy. J Korean Med Sci 2010;25:1291-5.
13. Yates DR, Roupret M, Drouin SJ, Comperat E, Ricci S, Lacave R, et al. Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrencefree survival nomogram prediction after radical prostatectomy. Prostate 2012;72:1382-8.
14. Thomas J, Gupta M, Grasso Y, Reddy CA, Heston WD, Zippe C, et al. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. J Clin Oncol 2002;20:3213-8.
15. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996;2:1445-51.
16. Heston WD. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology 1997;49:104-12.
17. Colombatti M, Grasso S, Porzia A, Fracasso G, Scupoli MT, Cingarlini S, et al. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS ONE 2009;4:e4608.
18. Rajasekaran SA, Christiansen JJ, Schmid I, Oshima E, Ryazantsev S, Sakamoto K, et al. Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol Cancer Ther 2008;7:2142-51.
19. Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. Prostate 2008;68:773-83.
20. Kovalenko PL, Zhang Z, Yu JG, Li Y, Clinton SK, Fleet JC. Dietary vitamin D and vitamin D receptor level modulate epithelial cell proliferation and apoptosis in the prostate. Cancer Prev Res 2011;4:1617-25.
21. Munetsuna E, Nakabayashi S, Kawanami R, Yasuda K, Ohta M, Arai MA, et al. Mechanism of the anti-proliferative action of 25-hydroxy-19- nor-vitamin D(3) in human prostate cells. J Mol Endocrinol 2011;47: 209-18.
22. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-34.
23. Demichelis F, Rubin MA. TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. J Clin Pathol 2007;60: 1185-6.
24. Yin L, Rao P, Elson P, Wang J, Ittmann M, Heston WD. Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression. PLoS ONE 2011;6:e21319.
25. Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH. Prostatespecific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 2006;26:5310-24.
26. Grant CL, Caromile LA, Durrani K, Rahman MM, Claffey KP, Fong GH, et al. Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization. PLoS ONE 2012;7:e41285.
27. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostatespecific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.
28. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57:3629-34.
29. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-81.
30. Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Muhlmann G, et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 2009;40:1754-61.
31. Hennekens CH, Eberlein K. A randomized trial of aspirin and beta-carotene among U.S. physicians. Prev Med 1985;14:165-8.
32. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008;300:2123-33.
33. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-35.
34. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
35. Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, et al. Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2012;308: 1871-80.
36. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007;121:1571-8.
37. Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol 2011;29:2378-85.
38. Dhillon PK, Barry M, Stampfer MJ, Perner S, Fiorentino M, Fornari A, et al. Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2009;18:595-600.
39. Mucci LA, Powolny A, Giovannucci E, Liao Z, Kenfield SA, Shen R, et al. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 2009;27:5627-33.
40. Tsui P, Rubenstein M, Guinan P. Correlation between PSMAand VEGF expression as markers for LNCaP tumor angiogenesis. J Biomed Biotechnol 2005;2005:287-90.
41. Krishnan AV, Peehl DM, Feldman D. The role of vitamin D in prostate cancer. Recent Results Cancer Res 2003;164:205-21.